Inflammatory and cardiac phenotypes are predictors for complications and outcomes in hospitalized covid-19 patients

It’s been shown that in patients with COVID-19 pneumonia, high levels of cytokines behave as an indicator of disease progression. We aim to characterize phenotypes according to inflammatory and cardiac biomarkers of patients hospitalized with SARS-CoV-2 and associate them to potential outcomes and complications. <bold>Methods:</bold> Patients admitted to the Hospital Clinic of Barcelona due to COVID-19 infection between 28th January-14th June 2021 were prospectively included. A blood sample during the first 48h from hospital admission was collected for each patient to measure interleukin (IL)-6 and NT-proBNP. Biomarkers concentrations were quantified by bead-based multiplex assays. For the analysis, patients were categorized into four groups depending on inflammation (IL-6 < or ³80 pg/mL) and cardiac phenotypes (NT-proBNP < or ³ 34.3 pg/mL). <bold>Results:</bold> One hundred sixty-nine patients were included (Figure 1) <fig><object-id>erj;64/suppl_68/PA5069/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> Cardiovascular comorbidities were more present in the cardiac phenotype. Inflammatory phenotype’ patients more frequently presented ARDS, while coagulation disorders were more commonly found in patients with both altered markers. Length of stay, ICU admission and IMV requirement were higher in the inflammatory phenotype, whereas mortality was higher when both phenotypes concurred. <bold>Conclusions:</bold> Inflammatory and cardiac phenotypes were associated with higher rates of complications and poor outcomes.